1Y Target$252.21Near-term target
5Y Target$482.38Compound horizon
10Y Target$1,255Long-dated conviction
FCF$1.1bTTM · 03/26C+FCF $1.1b — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+19.1%TTM YoYB+Revenue +19.1% — above sector median, healthy trajectory
D/E1.20C+D/E 1.20 — moderately levered, watch interest coverage
P/S3.4xBP/S 3.4x — in line with software/tech peers
PEG1.00B+PEG 1.00 — near fair value, classic Lynch benchmark (1.0)
Why now
Biotechnology · market cap $15.0b. Trading near 52-week high of $243.32 — momentum setup, limited technical margin of safety. Revenue growing +19%, comfortably above the S&P median. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $252.21 (implying +5% upside).
Moat
FCF converts 3883% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Net margin 0.7% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 1% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $252.21 (19-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $482.38 — requires the platform / technology to reach commercial scale. 10 yr $1,255 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.